Cargando…

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression

Detalles Bibliográficos
Autores principales:	Yan, Xin, Xu, Zefeng, Zhang, Peihong, Sun, Qi, Jia, Yujiao, Qin, Tiejun, Qu, Shiqiang, Pan, Lijuan, Li, Zhanqi, Liu, Jinqin, Song, Zhen, Gao, Qingyan, Jiao, Meng, Gong, Jingye, Wang, Huijun, Li, Bing, Xiao, Zhijian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119377/ https://www.ncbi.nlm.nih.gov/pubmed/37080954 http://dx.doi.org/10.1038/s41408-023-00829-3

Ejemplares similares

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
por: Li, Bing, et al.
Publicado: (2017)

ASXL2 mutated myelodysplastic syndrome in a novel germline G6b variant
por: Qu, Shiqiang, et al.
Publicado: (2022)

ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms
por: Shi, Zhongxun, et al.
Publicado: (2022)

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
por: Cui, Yajuan, et al.
Publicado: (2015)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy
por: Qu, Shiqiang, et al.
Publicado: (2023)

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms
por: Zhang, Yudi, et al.
Publicado: (2022)

Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations
por: Nielsen, Helene Myrtue, et al.
Publicado: (2017)

Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
por: Luo, Xueping, et al.
Publicado: (2018)

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
por: Wu, Junying, et al.
Publicado: (2022)

Publisher Correction: Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations
por: Nielsen, Helene Myrtue, et al.
Publicado: (2018)

Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis
por: Wang, Ziqing, et al.
Publicado: (2021)

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder
por: Huang, Huijun, et al.
Publicado: (2021)

P985: THE ALLELIC RATIO OF DRIVER AND ASXL1 MUTATIONS IS PROGNOSTICALLY RELEVANT IN PMF
por: Coltro, G., et al.
Publicado: (2022)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
por: Balasubramani, Anand, et al.
Publicado: (2015)

Conventional interferon-a 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center
por: Liu, Dan, et al.
Publicado: (2022)

RBC distribution width predicts thrombosis risk in polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

ASXL1/2 mutations and myeloid malignancies
por: Medina, Edward A., et al.
Publicado: (2022)

CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia
por: Cui, Yajuan, et al.
Publicado: (2014)

Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics
por: Gilani, Jaleed Ahmed, et al.
Publicado: (2019)

ASXL1 mutations in Chinese patients with essential thrombocythemia
por: Nie, Yan-Bo, et al.
Publicado: (2018)

ASXL1 plays an important role in erythropoiesis
por: Shi, Hui, et al.
Publicado: (2016)

Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins
por: Huang, Huijun, et al.
Publicado: (2023)

Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review
por: Alshemmari, Salem H., et al.
Publicado: (2016)

The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis
por: Genovese, Elena, et al.
Publicado: (2022)

SETBP1 Mutations Drive Leukemic Transformation in ASXL1-Mutated MDS
por: Inoue, Daichi, et al.
Publicado: (2014)

Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization for detecting chromosome abnormalities in myelodysplastic syndromes: A retrospective study
por: Ai, Xiaofei, et al.
Publicado: (2021)

Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes
por: Wang, Jingya, et al.
Publicado: (2016)

Role of ASXL1 mutation in impaired hematopoiesis and cellular senescence
por: Uni, Masahiro, et al.
Publicado: (2018)

RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia
por: Bera, Rabindranath, et al.
Publicado: (2019)

Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre
por: Huang, Huijun, et al.
Publicado: (2020)

Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network
por: Xia, Yu-Kun, et al.
Publicado: (2020)

ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
por: Wang, Yu-Hung, et al.
Publicado: (2020)

Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R
por: Li, Bing, et al.
Publicado: (2016)

Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish
por: Fang, Xiao, et al.
Publicado: (2021)

Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis
por: Ding, Nan, et al.
Publicado: (2017)

Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing
por: Ferrer-Marín, Francisca, et al.
Publicado: (2013)

Pathological ASXL1 Mutations and Protein Variants Impair Neural Crest Development
por: Matheus, Friederike, et al.
Publicado: (2019)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5r6a8b5osvshi61lh2tfia7b88